News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter

Prof. David Townsend Awarded The Milabs Advanced Imaging Scientist Award 2014

5/20/2014 9:52:35 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Utrecht, The Netherlands MILabs BV is proud to announce that the Advanced Imaging Scientist award 2014 will be presented to Prof. Dr. David William Townsend for his groundbreaking scientific contribution to diagnose cancer at the Utrecht Life Science seminar on May 19th 2014. Utrecht Life Science has organized together with MILabs B.V. a seminar at University Medical Center Utrecht on May 19th which highlights the technological development which has led to the current application of PET/CT for diagnosis of cancer and research in thousands of hospitals world wide. David W. Townsend, PhD, FRCR, DSc (Hon), currently director of the A*STAR-NUS Clinical Imaging Research Centre in Singapore, has designed and built the first rotating partial ring PET scanner at the faculty of Geneva University Hospital in 1980. In 1995, he was the Principal Investigator on the first proposal to design and build a combined PET/CT scanner, which was named by TIME Magazine as the Medical Invention of the Year 2000. Shortly thereafter PET/CT started to revolutionize daily clinical practice, since it collects anatomical and functional information non-invasively, enabling to accurately localize e.g. tumors. This allows personalized treatment of patients in a wide variety of diseases.

“I am extremely proud to present this MILabs award to David Townsend, as he has shown that physicists, do make fundamental changes in life threatening diseases such as cancer” says Freek Beekman, CEO of MILabs B.V.

“Moreover his visit to the Utrecht Science Park proofs that combined public, private and educational efforts underpin our commitment to the open innovation network in Utrecht ” continues Freek Beekman.

About MILabs

MILabs provides high-end preclinical imaging solutions for biomedical and pharmaceutical research. Today these systems contribute worldwide to the development of new diagnostic solutions and therapies for diseases such as cancer, cardiac, neurodegenerative diseases and diabetes. The patented technologies fully embedded in MILabs’ multimodality imaging platforms allows to smoothly combine SPECT, PET, CT and MRI pre-clinical imaging with the highest image quality currently available. For more information please visit us on :

Help employers find you! Check out all the jobs and post your resume.

Read at

comments powered by Disqus